Johns Hopkins HIV Guide
Didanosine
INDICATIONS
FDA
FDA
- Treatment of HIV infection in combination with other antiretrovirals.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: February 20, 2025
Citation
, Kathryn Dzintars, Pharm.D. BCPS, and Janessa Smith. "Didanosine." Johns Hopkins HIV Guide, The Johns Hopkins University, 2025. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine.
K, Smith J. Didanosine. Johns Hopkins HIV Guide. The Johns Hopkins University; 2025. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine. Accessed October 16, 2025.
, K., & Smith, J. (2025). Didanosine. In Johns Hopkins HIV Guide. The Johns Hopkins University. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine
K, Smith J. Didanosine [Internet]. In: Johns Hopkins HIV Guide. The Johns Hopkins University; 2025. [cited 2025 October 16]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Didanosine
ID - 545057
A1 - ,Kathryn Dzintars, Pharm.D. BCPS,
AU - Smith,Janessa,Pharm.D. BCPS
Y1 - 2025/02/20/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545057/all/Didanosine
PB - The Johns Hopkins University
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
